Risk factors of death or chronic renal replacement therapy requirements in patients with thrombotic microangiopathies without ADAMTS-13 deficiency.
Uriol-Rivera MG, Andrade BL, Bonet AM, Mulet AO, Ruiz CB, Parraga LP, Lumbreras J, Rota JIA, Servalos MF, Balaguer JF, Ferreres LP, Valles MJP, Valero RMRG, Sanchez ST, Martin AG, Garcia JR, Cobo CG, Ramis-Cabrer D; Son Espases Multidisciplinary Team for the management of Thrombotic Microangiopathy.
Uriol-Rivera MG, et al.
Eur J Haematol. 2024 Oct;113(4):510-520. doi: 10.1111/ejh.14261. Epub 2024 Jul 2.
Eur J Haematol. 2024.
PMID: 38955806